Quick Answer
CASI Pharmaceuticals, Inc. reported Net Income of -$39.26 million for fiscal year 2024.
CASI Pharmaceuticals, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2024 | -$39.26M | -45.6% |
| 2023 | -$26.96M | +34.3% |
| 2022 | -$41.01M | -11.9% |
| 2021 | -$36.65M | +24.1% |
| 2020 | -$48.29M | — |
- CASI Pharmaceuticals, Inc. showed a decrease of -45.6% in Net Income compared to the prior fiscal year.
- Over the 2020–2024 period, CASI Pharmaceuticals, Inc.’s net income has grown by 18.7% (from -$48.29 million to -$39.26 million).
- The most recent figure is from CASI Pharmaceuticals, Inc.’s fiscal year 2024 report (Form 20-F), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: